Shares of Zoetis Inc. (NYSE:ZTS – Get Rating) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $215.17.
→ Profit From the Commercial Solar Boom? (From Investing Trends)
A number of research firms have recently issued reports on ZTS. The Goldman Sachs Group cut their price objective on Zoetis from $207.00 to $180.00 and set a “buy” rating for the company in a research report on Friday, November 4th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Thursday, November 3rd. JPMorgan Chase & Co. lowered their target price on Zoetis from $250.00 to $225.00 and set an “overweight” rating on the stock in a research note on Monday, October 17th. StockNews.com initiated coverage on Zoetis in a research note on Wednesday, October 12th. They set a “buy” rating on the stock. Finally, Morgan Stanley lowered their target price on Zoetis from $264.00 to $248.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 15th.
Hedge Funds Weigh In On Zoetis
A number of hedge funds have recently added to or reduced their stakes in ZTS. Psagot Value Holdings Ltd. Israel acquired a new stake in shares of Zoetis during the 3rd quarter valued at $25,000. Worth Asset Management LLC bought a new stake in Zoetis during the 1st quarter worth approximately $26,000. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its holdings in Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares in the last quarter. EWG Elevate Inc. purchased a new position in shares of Zoetis in the 4th quarter worth approximately $27,000. Finally, McClarren Financial Advisors Inc. purchased a new position in shares of Zoetis in the 3rd quarter worth approximately $31,000. Institutional investors own 90.23% of the company’s stock.
Zoetis Stock Performance
ZTS opened at $161.95 on Friday. Zoetis has a 12-month low of $124.15 and a 12-month high of $206.25. The stock has a market cap of $75.48 billion, a price-to-earnings ratio of 36.97, a PEG ratio of 2.77 and a beta of 0.73. The business has a 50 day moving average of $150.42 and a 200-day moving average of $157.15. The company has a quick ratio of 1.48, a current ratio of 2.27 and a debt-to-equity ratio of 1.12.
Zoetis (NYSE:ZTS – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.24 by ($0.03). Zoetis had a net margin of 25.82% and a return on equity of 48.41%. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $2.08 billion. During the same period in the previous year, the business earned $1.25 earnings per share. The business’s quarterly revenue was up .6% on a year-over-year basis. On average, equities research analysts expect that Zoetis will post 4.87 earnings per share for the current year.
Zoetis Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, January 20th will be paid a dividend of $0.375 per share. This represents a $1.50 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date is Thursday, January 19th. This is a positive change from Zoetis’s previous quarterly dividend of $0.33. Zoetis’s dividend payout ratio (DPR) is 29.68%.
About Zoetis
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Zoetis wasn’t on the list.
While Zoetis currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
